The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Chugai, Japan Govt Cut Supply Deal for COVID-19 Antibody Cocktail
Chugai Pharmaceutical said on May 10 that it has agreed with the Japanese government to secure this year’s domestic supply for its COVID-19 antibody cocktail, which was originated by Regeneron Pharmaceuticals, if approved. The antibody cocktail pairing casirivimab and imdevimab,…
To read the full story
Related Article
- Japan Approves Ronapreve to Prevent Symptomatic COVID-19
November 5, 2021
- Ronapreve Clears Key Panel for COVID-19 Prevention, SC Use
November 5, 2021
- Ronapreve Up for PAFSC Review for Preventive Use on Nov. 4
October 29, 2021
- Chugai Seeks Japan Nod for Ronapreve in Prophylaxis, Asymptomatic COVID-19
October 12, 2021
- Japan Approves COVID-19 Antibody Cocktail, 1st Drug for Mild Cases
July 20, 2021
- Chugai’s Antibody Cocktail Up for PAFSC Review on July 19, 4th COVID-19 Drug If Approved
July 13, 2021
- Chugai Files Regeneron’s Antibody Cocktail in Japan
June 30, 2021
- Chugai Presses on with Japan Development of 3 COVID-19 Drugs, Aims for Antibody Cocktail Filing in 2021: President
May 14, 2021
- Chugai Eyes Japan Submission for COVID-19 Antibody Cocktail by Year-End
April 23, 2021
- Chugai to Develop Regeneron’s COVID-19 Antibody Cocktail in Japan
December 11, 2020
- Chugai, Roche Discussing Japan Development of Regeneron's COVID-19 Antibody Cocktail
October 16, 2020
BUSINESS
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
- Drug Wholesalers Slam “No-Discussion” Decision on FY2027 Off-Year Price Revision
December 25, 2025
- JCR Earns Japan Rights to DMD Drug from Italfarmaco
December 25, 2025
- Fujifilm Completes Major Biologics CDMO Plant in Toyama, Eyes 2027 Start-Up
December 25, 2025
- Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…